CN115607506B - 含重组人碱性成纤维细胞生长因子无水膏剂制备方法 - Google Patents
含重组人碱性成纤维细胞生长因子无水膏剂制备方法 Download PDFInfo
- Publication number
- CN115607506B CN115607506B CN202211625937.9A CN202211625937A CN115607506B CN 115607506 B CN115607506 B CN 115607506B CN 202211625937 A CN202211625937 A CN 202211625937A CN 115607506 B CN115607506 B CN 115607506B
- Authority
- CN
- China
- Prior art keywords
- paste
- hydroxyapatite
- growth factor
- fibroblast growth
- recombinant human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108700005467 recombinant KCB-1 Proteins 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 42
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 238000003756 stirring Methods 0.000 claims abstract description 26
- 235000011187 glycerol Nutrition 0.000 claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 11
- 230000009969 flowable effect Effects 0.000 claims abstract description 4
- 239000008176 lyophilized powder Substances 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims abstract description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 40
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 40
- GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 claims description 29
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 22
- 239000002131 composite material Substances 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 11
- 229910052901 montmorillonite Inorganic materials 0.000 claims description 11
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- 239000003085 diluting agent Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 5
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 229960004275 glycolic acid Drugs 0.000 claims description 5
- ICAKDTKJOYSXGC-UHFFFAOYSA-K lanthanum(iii) chloride Chemical compound Cl[La](Cl)Cl ICAKDTKJOYSXGC-UHFFFAOYSA-K 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 229920001661 Chitosan Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- 229930182555 Penicillin Natural products 0.000 claims description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- 238000011068 loading method Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229940049954 penicillin Drugs 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 238000000859 sublimation Methods 0.000 claims description 3
- 230000008022 sublimation Effects 0.000 claims description 3
- 239000000243 solution Substances 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 16
- 239000007864 aqueous solution Substances 0.000 abstract description 10
- 239000002674 ointment Substances 0.000 abstract description 8
- 238000003860 storage Methods 0.000 abstract description 5
- 239000000017 hydrogel Substances 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 29
- 208000027418 Wounds and injury Diseases 0.000 description 29
- 238000012360 testing method Methods 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 16
- 239000000499 gel Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 10
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 10
- 230000002209 hydrophobic effect Effects 0.000 description 10
- 239000003814 drug Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000029663 wound healing Effects 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 239000002270 dispersing agent Substances 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 5
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 206010053615 Thermal burn Diseases 0.000 description 4
- 238000001804 debridement Methods 0.000 description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 4
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000006184 cosolvent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 3
- 229960001008 heparin sodium Drugs 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000011146 sterile filtration Methods 0.000 description 3
- 229940074410 trehalose Drugs 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 229940119744 dextran 40 Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 239000005152 Cholesterol Laurate Substances 0.000 description 1
- 239000005149 Cholesterol Linoleate Substances 0.000 description 1
- RMLFYKFCGMSLTB-ZBDFTZOCSA-N Cholesteryl laurate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCC)C1 RMLFYKFCGMSLTB-ZBDFTZOCSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- NAACPBBQTFFYQB-UHFFFAOYSA-N Linolsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCC=CCCCCC)C2 NAACPBBQTFFYQB-UHFFFAOYSA-N 0.000 description 1
- SJDMTGSQPOFVLR-UHFFFAOYSA-N Myristinsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCC)C2 SJDMTGSQPOFVLR-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- BBJQPKLGPMQWBU-UHFFFAOYSA-N Palmitinsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCC)C2 BBJQPKLGPMQWBU-UHFFFAOYSA-N 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- IMXSFYNMSOULQS-BEDFLICRSA-N cholesteryl arachidonate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC)C1 IMXSFYNMSOULQS-BEDFLICRSA-N 0.000 description 1
- WBOQXYUYHINMOC-FTAWAYKBSA-N cholesteryl behenate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCCCCCC)C1 WBOQXYUYHINMOC-FTAWAYKBSA-N 0.000 description 1
- NAACPBBQTFFYQB-LJAITQKLSA-N cholesteryl linoleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)C1 NAACPBBQTFFYQB-LJAITQKLSA-N 0.000 description 1
- SJDMTGSQPOFVLR-ZPQCIJQQSA-N cholesteryl myristate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCC)C1 SJDMTGSQPOFVLR-ZPQCIJQQSA-N 0.000 description 1
- BBJQPKLGPMQWBU-JADYGXMDSA-N cholesteryl palmitate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCC)C1 BBJQPKLGPMQWBU-JADYGXMDSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000011368 organic material Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940117972 triolein Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开了含重组人碱性成纤维细胞生长因子无水膏剂制备方法,包括以下步骤:将甘油添加到冻干粉中,并且混合/搅拌直到所有粉末颗粒都与甘油混合均匀,形成面团状糊剂;然后将丙二醇添加到上述糊剂中,并混合/搅拌,以形成最终的,可流动的膏剂;本发明涉及的无水膏剂较好的解决了在水溶液或水凝胶内无法长期维持稳定,容易失活,另外,溶液剂使用在创面上,不易长期留存,提高了使用频率,上述存在的问题,既方便使用,又便于储存,而且膏剂相较溶液,可以更长时间停留在创面处,提高治疗效果。
Description
技术领域
本发明涉及生长因子膏剂技术领域,具体涉及含重组人碱性成纤维细胞生长因子无水膏剂制备方法。
背景技术
碱性成纤维细胞生长因子(bFGF)是目前广泛应用于伤口愈合领域临床治疗的生物制品,现有产品多为冻干制剂、溶液剂或凝胶剂等。冻干制剂在使用前需溶解在生理盐水或注射用水里,较为耗费时间。溶液剂或凝胶剂虽然试用便利,但是因为含有大量水分,蛋白成分在其内保存稳定性存在问题,容易失活,对储存条件有较严格的要求。本发明的目的是提供一种用于制备具有治疗或药用价值的糊状可涂抹的bFGF组合物,其可以容易地运用于需要的部位。该制备方法得到的是一种不含水的膏剂,里面添加的是疏水性液体。疏水性液体可以提供bFGF的流动性,使保持bFGF在患处使用的功能。该膏剂易于使用、稳定且具有效的创面修复功能。
Rh-bFGF在水溶液或水凝胶内无法长期维持稳定,容易失活。另外,溶液剂使用在创面上,不易长期留存,提高了使用频率,降低了治疗效果,也提升了使用成本。
发明内容
针对现有技术的缺陷,本发明的目的是提供含重组人碱性成纤维细胞生长因子无水膏剂制备方法,以解决上述背景技术中提出的问题。
本发明解决技术问题采用如下技术方案:
本发明提供了含重组人碱性成纤维细胞生长因子无水膏剂制备方法,包括以下步骤:
将甘油添加到冻干粉中,并且混合/搅拌直到所有粉末颗粒都与甘油混合均匀,形成面团状糊剂;然后将丙二醇添加到上述糊剂中,并混合/搅拌,以形成最终的,可流动的膏剂。
优选地,所述冻干粉包括以下重量份原料:
重组人碱性成纤维细胞生长因子 20000-50000IU、蛋白保护剂 5-10mg 和稀释剂50-100mg。
优选地,所述蛋白保护剂选自人血白蛋白、甘露醇和聚乙二醇,优选人血白蛋白。
优选地,所述稀释剂选自甘露醇、乳糖醇或葡萄糖。
优选地,所述冻干粉的制备工艺为:将重组人碱性成纤维细胞生长因子、蛋白保护剂和稀释剂用注射用水溶解后,用 0.22μm 的滤膜无菌过滤,分装于西林瓶中,装盘后送入冻干机中,先将样品在 -20℃--40℃预冻 2-5 小时,然后开启冷凝器,开启真空系统,开始升温升华,完毕后在 15℃-40℃干燥 4-8 小时,即得。
优选地,所述混合/搅拌的转速为550-1000r/min。
优选地,所述丙二醇添加到糊剂后还加入羟基磷灰石复合改性蒙脱土,加入量为丙二醇总量5-10%。
优选地,所述羟基磷灰石复合改性蒙脱土的制备方法为:
S01:将羟基磷灰石按照重量比1:6加入到十二烷基硫酸钠溶液中,然后加入羟基磷灰石总量5-10%的盐酸,搅拌均匀;
S02:随后加入羟基磷灰石2-5%的壳聚糖、羟基磷灰石1-5%的羟基乙酸,搅拌充分,得到羟基磷灰石复合液;
S03:将蒙脱土送入到350-400℃下热处理10-20min,随后以1-5℃/min的速率将至室温,然后送入到4-6倍的盐酸溶液中,搅拌均匀;
S04:随后加入蒙脱土总量5-10%的羟乙基纤维素、1-5%的氯化镧,搅拌充分,再水洗、干燥;
S05:将S04产物按照重量比1:5送入到S02中,继续反应充分,最后水洗、干燥,得到羟基磷灰石复合改性蒙脱土。
优选地,所述十二烷基硫酸钠溶液、盐酸溶液的质量分数分别为10-20%、5-10%。
优选地,所述甘油、冻干粉、丙二醇的物质质量比为1.2:1:0.5。
与现有技术相比,本发明具有如下的有益效果:
本发明涉及的无水膏剂较好的解决了上述存在的问题,既方便使用,又便于储存,而且膏剂相较溶液,可以更长时间停留在创面处,提高治疗效果;涉及的无水膏剂包含重组人碱性成纤维细胞生长因子(rh-bFGF),一种或几种有机分散剂,如甘油、丙二醇、大豆油等。将上述活性成分和分散剂按一定比例混合制成均匀膏体即可。在本公开的任何方面的一些实施例中,疏水分散剂选自包含一种或多种的油:大豆油、橄榄油、胆固醇油酸酯、玉米油、三油酸甘油酯、红花油、角鲨烯、角鲨烷、矿物油和十二烷,以及它们的任何混合物;使用无水有分散剂,将rh-bFGF悬浮于分散剂中制成膏体。活性蛋白在无水环境下可以稳定保存较长时间,极大降低了储存和运输的成本,也保证了产品的药效。同时,膏剂可以在一段时间内留存于创面,并缓释期内的活性成分,降低了使用频率和成本。
附图说明
图1是3种处方制剂在25℃的活性稳定性示意图;
图2是各组豚鼠烫伤创面愈合结果比较图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
静态阶段粘度越高膏体越稳定
术语“疏水液体”、“疏水溶剂”、“疏水分散剂”、“疏水介质”、“油”、“油性液体”、“油性介质”、“非极性溶剂”、“非极性液体”或“疏水性液体”(也可称为“亲脂性液体”),其在本文中可互换使用,是在室温左右为液体且通常不可溶解的物质,或具有有限的溶于水溶液,溶于非极性有机溶剂。
油性液体具有油性构成并且包括例如天然和合成制备的油如橄榄油、其他植物和动物衍生的油,以及无机油如硅油和/或其他矿物油。
非限制性类型的疏水液体包括有机物质,例如烷烃,特别是长链烷烃、环烷烃,包括双环化合物、芳基(取代的和未取代的)和脂肪酸。
其他非限制性类型的疏水液体包括肉豆蔻酸胆固醇酯、月桂酸胆固醇酯、十二烷酸胆固醇酯、棕榈酸胆固醇酯、花生四烯酸胆固醇酯、山萮酸胆固醇酯、亚油酸胆固醇酯、亚麻酸胆固醇酯、油酸胆固醇酯、玉米油酸胆固醇酯、油酸胆固醇油、橄榄油油酸甘油酯/胆固醇油酸酯混合物、红花油、角鲨烯、角鲨烷、十二烷及其任何混合物,例如橄榄油和胆固醇油酸酯,以及甘油三油酸酯/胆固醇油酸酯混合物。
请参阅图1-2,本实施例的含重组人碱性成纤维细胞生长因子无水膏剂制备方法,包括以下步骤:
将甘油添加到冻干粉中,并且混合/搅拌直到所有粉末颗粒都与甘油混合均匀,形成面团状糊剂;然后将丙二醇添加到上述糊剂中,并混合/搅拌,以形成最终的,可流动的膏剂。
本实施例的冻干粉包括以下重量份原料:
重组人碱性成纤维细胞生长因子 20000-50000IU、蛋白保护剂 5-10mg 和稀释剂50-100mg。
本实施例的蛋白保护剂选自人血白蛋白、甘露醇和聚乙二醇,优选人血白蛋白。
本实施例的稀释剂选自甘露醇、乳糖醇或葡萄糖。
本实施例的冻干粉的制备工艺为:将重组人碱性成纤维细胞生长因子、蛋白保护剂和稀释剂用注射用水溶解后,用 0.22μm 的滤膜无菌过滤,分装于西林瓶中,装盘后送入冻干机中,先将样品在 -20℃--40℃预冻 2-5 小时,然后开启冷凝器,开启真空系统,开始升温升华,完毕后在 15℃-40℃干燥 4-8 小时,即得。
本实施例的混合/搅拌的转速为550-1000r/min。
本实施例的丙二醇添加到糊剂后还加入羟基磷灰石复合改性蒙脱土,加入量为丙二醇总量5-10%。
本实施例的羟基磷灰石复合改性蒙脱土的制备方法为:
S01:将羟基磷灰石按照重量比1:6加入到十二烷基硫酸钠溶液中,然后加入羟基磷灰石总量5-10%的盐酸,搅拌均匀;
S02:随后加入羟基磷灰石2-5%的壳聚糖、羟基磷灰石1-5%的羟基乙酸,搅拌充分,得到羟基磷灰石复合液;
S03:将蒙脱土送入到350-400℃下热处理10-20min,随后以1-5℃/min的速率将至室温,然后送入到4-6倍的盐酸溶液中,搅拌均匀;
S04:随后加入蒙脱土总量5-10%的羟乙基纤维素、1-5%的氯化镧,搅拌充分,再水洗、干燥;
S05:将S04产物按照重量比1:5送入到S02中,继续反应充分,最后水洗、干燥,得到羟基磷灰石复合改性蒙脱土。
本实施例的十二烷基硫酸钠溶液、盐酸溶液的质量分数分别为10-20%、5-10%。
rh-bFGF水溶液剂(用作效果比对)的配方及制备工艺
本发明所用的重组人碱性成纤维细胞生长因子水溶液剂,包括有重组人碱性成纤维细胞生长因子(rh-bFGF)原液0.1%-100%(W/W),可用药的辅料0.1%-100%(W/W);
所述原液,其组成为:有效治疗量的重组人碱性成纤维细胞生长因子
共制100瓶;
所述可用药的辅料:可由以下物质的一种或几种构成:
右旋糖酐40、海藻糖(50g)
上述药液的制备方法为:将处方量的肝素钠(30g)、rh-bFGF(10g)混合,经0.22m滤膜无菌过滤;将处方量的甘露醇(25g)、海藻糖(50g)溶于注射用水加至1000ml,经0.22m滤膜无菌过滤。将上述两种无菌液混合均匀分装到无菌玻璃瓶内即得。
2、rh-bFGF普通凝胶剂(用作效果比对)的配方及制备工艺
本发明所用的重组人碱性成纤维细胞生长因子凝胶,包括有重组人碱性成纤维细胞生长因子(rh-bFGF)原液0.1%-100%(W/W),可用药的辅料0.1%-100%(W/W),
所述原液,其组成为:
有效治疗量的重组人碱性成纤维细胞生长因子(rh-bFGF)0.01%-1%(g/g) 10g
NaCl 0.01%-20%
磷酸盐缓冲液 2mMol-200 mMol
注射用水适量 (加至1000ml)
所述可用药的辅料可选取以下得物质:卡波姆940NF、透明质酸钠、海藻糖、甘露醇、右旋糖酐40、肝素钠。
上述凝胶的制备方法为:
称卡波姆940NF 10g于1L烧杯中,加入250ml注射用水,使其自然溶胀,溶胀后加入4%氢氧化钠,边加边搅拌,调pH至7.0(约140ml),得到最大粘稠度基质(Ⅰ)。
称透明质酸钠2.5g于500ml烧杯中,加入400ml注射用水使其自然溶胀成胶溶液(Ⅱ)。
称右旋糖酐2.5g于500ml烧杯中,加入注射用水200ml,必要时加热使其溶解成右旋糖酐溶液,用0.22m滤膜无菌过滤(Ⅲ)。
把(Ⅱ)加入(Ⅰ)中,搅拌成凝胶基质(Ⅳ)。
把(Ⅳ)高压灭菌(121℃,15min,0.10Mpa),灭菌后自然放冷。
将bFGF、肝素钠按3:1比例混合,过滤除菌,并加入到(Ⅲ)中,成溶液(Ⅴ)。
把溶液(Ⅴ)加入到灭菌后得凝胶基质(Ⅳ)中,边加边搅拌,此过程温度不得超过37℃,并补加灭菌注射用水至1000ml成bFGF凝胶半成品。
使用药用铝管,无菌操作进行分装。
本实施例的甘油、冻干粉、丙二醇的物质质量比为1.2:1:0.5。
制剂效果试验验证
一、 rh-bFGF水溶液剂、rh-bFGF普通凝胶剂、rh-bFGF无水膏剂的质量控制及稳定性研究
1.长期试验
将rh-bFGF水溶液剂、rh-bFGF普通凝胶剂、rh-bFGF无水膏剂样品装于内涂层封口铝管中,25℃恒温室存放,分别于第0个月、3个月、6个月、9个月、12个月、15个月、18个月、21个月、24个月末抽样检测其相对活性(%)。
从长期试验来看,3种处方药剂在25℃存放的相对活性均随存放时间的延长呈降低的趋势,但不同的是,rh-bFGF无水膏剂的相对活性较rh-bFGF水溶液剂和rh-bFGF普通凝胶剂降低的更缓慢,在25℃存放24个月,其相对活性始终保持在90%以上的水平,而rh-bFGF水溶液剂和rh-bFGF普通凝胶剂在25℃存放24个月后,两者的相对活性则均低于60%。由此可见,rh-bFGF无水膏剂的稳定性更好(见图1),可用于工业化生产与应用。
形成这种差异的原因可能是,糖类、多元醇、氨基酸及其衍生物、无机盐、甘油、多聚物如聚乙二醇(PEG)等一般被称为蛋白质的共溶剂。生化学家常常使用高浓度(1-4mol)共溶剂来稳定蛋白质或细胞器。过去,其稳定机理一直被认为是在蛋白质分子表面形成一个保护壳。近几年来的研究表明,共溶剂对蛋白质的保护作用机制实际上是共溶剂的加入改变了溶液的热力学性质,使得天然蛋白质的稳定性得到增强,理论上称优先排阻作用。共溶剂从蛋白质表面的优先排阻并不是说共溶剂分子绝对不能渗透到蛋白质表面并与之结合,而是在蛋白质表面完全水化和共溶剂完全结合之间建立起一种平衡。
甘油则除了对蛋白质的非极性表面有很好的稳定作用外,还能诱导蛋白亚基的自我聚合并具有减轻器壁吸附和防冻的作用。
二、本发明含rh-bFGF无水膏剂促进表皮细胞生长及烫伤创面愈合的试验研究
1、试验材料
1.1试验动物:SD大鼠,雌雄各半,体重280-300g;
1.2试验药物:本发明实施例3制备的含重组人碱性成纤维细胞生长生长因子无水膏剂;不含 rb-b FGF 的生理盐水。
1.3试验组别:用药组:向清创后的创面直接涂抹含rh-bFGF无水膏剂;
对照组:向清创后的创面直接涂抹不含 rb-b FGF 的生理盐水。
2、试验方法
动物烫伤创面模型:豚鼠在试验期间均正常饮水,普通饮食,于试验前将豚鼠背部脱毛。
用80℃恒温水通过一玻璃圆筒分别烫伤豚鼠背部皮肤,造成Ⅱ度烫伤模型。豚鼠造模后
随机分为用药组和对照组,每组各10只。用药组和对照组每日分别给予相应药物4次,单独饲养,连续14天。观察创面愈合情况,通过对伤口面积的测定来记录皮肤结痴时间和创面愈合时间。
伤口愈合率=1-测试时间伤口面积/初始伤口面积
3、试验结果
图2结果表明:本发明含重组人碱性成纤维细胞生长因子无水膏剂可明显降低豚鼠背部烫伤皮肤结痴及愈合的时间,且愈合程度较对照组更明显,说明本发明含重组人碱性成纤维细胞生长因子无水膏剂对烫伤创面愈合有显著促进作用。
三、本发明含rh-bFGF无水膏剂治疗烧糖尿病创面的试验研究
1、试验材料
1.1试验动物:40只雄性C57BL/6J小鼠,SPF级,七八周龄,体质量约20 g,用于制备糖尿病创面模型;
1.2试验药物:本发明实施例3制备的含重组人碱性成纤维细胞生长生长因子无水膏剂;不含 rb-bFGF 的生理盐水。
2、试验组别:糖尿病创面bFGF无水制剂治疗组:向清创后的创面直接涂抹含rh-bFGF无水膏剂;
糖尿病创面空白对照组:向清创后的创面直接涂抹不含 rb-bFGF 的生理盐水。
3、试验方法
构建糖尿病小鼠模型:取七八周龄雄性C57BL/6J小鼠40只,禁食12 h后,腹腔注射链脲佐菌素(100 mg/kg),连续注射2 d。2周后用全自动血糖监测仪测定血糖,当连续2 d的血糖水平>16.7 mmol/L定义为糖尿病小鼠造模成功。
构建糖尿病小鼠创面模型及给药:糖尿病造模成功后制作创面模型,以异氟烷呼吸麻醉小鼠,在其背部应用打孔器制造2个直径6 mm的对称创面。每只小鼠单笼饲养,便于长期创面观察。
创面大体形态及愈合率的观察:每天观察小鼠创面恢复情况,直到创面完全愈合为止。于第0,7,14天测量创面面积,用Image J软件计算创面愈合率。
4、试验结果
由表1可知:和空白对照组相比,使用本发明无水膏剂的小鼠创面愈合程度更好。
表1. bFGF无水制剂治疗组和空白对照组糖尿病模型创面愈合情况(%)
组别 | n | 0级 | 1级 | 2级 | 3级 |
糖尿病创面bFGF无水制剂治疗组 | 20 | 11 | 6 | 3 | 0 |
糖尿病创面空白对照组 | 20 | 2 | 3 | 7 | 8 |
无水膏剂较好的解决了上述存在的问题,既方便使用,又便于储存,而且膏剂相较溶液,可以更长时间停留在创面处,提高治疗效果;同时,膏剂可以在一段时间内留存于创面,并缓释期内的活性成分,降低了使用频率和成本。
本实施例的羟基磷灰石复合改性蒙脱土的制备方法为:
S01:将羟基磷灰石按照重量比1:6加入到十二烷基硫酸钠溶液中,然后加入羟基磷灰石总量5-10%的盐酸,搅拌均匀;
S02:随后加入羟基磷灰石2-5%的壳聚糖、羟基磷灰石1-5%的羟基乙酸,搅拌充分,得到羟基磷灰石复合液;
S03:将蒙脱土送入到350-400℃下热处理10-20min,随后以1-5℃/min的速率将至室温,然后送入到4-6倍的盐酸溶液中,搅拌均匀;
S04:随后加入蒙脱土总量5-10%的羟乙基纤维素、1-5%的氯化镧,搅拌充分,再水洗、干燥;
S05:将S04产物按照重量比1:5送入到S02中,继续反应充分,最后水洗、干燥,得到羟基磷灰石复合改性蒙脱土。
本实施例的十二烷基硫酸钠溶液、盐酸溶液的质量分数分别为10-20%、5-10%。
对比例1:
与羟基磷灰石复合改性蒙脱土制备方法不同是,未加入蒙脱土。
对比例2:
与羟基磷灰石复合改性蒙脱土制备方法不同是,未加入氯化镧。
对比例3:
与羟基磷灰石复合改性蒙脱土制备方法不同是,采用羟基磷灰石、蒙脱土按照制备方法的配比直接混合。
对比例4:
与羟基磷灰石复合改性蒙脱土制备方法不同是,未加入羟基乙酸。
从对比例1-4中可看出,羟基磷灰石复合改性蒙脱土制备方法不同,相对愈合率性能有变差趋势,同时加入本发明的方法制备的羟基磷灰石复合改性蒙脱土,性能有显著改进趋势,同时采用羟基磷灰石、蒙脱土按照制备方法的配比直接混合,性能改进不明显,只有采用本发明的方法制备的羟基磷灰石复合改性蒙脱土对产品的性能效果显著。
对于本领域技术人员而言,显然本发明不限于上述示范性实施例的细节,而且在不背离本发明的精神或基本特征的情况下,能够以其他的具体形式实现本发明。因此,无论从哪一点来看,均应将实施例看作是示范性的,而且是非限制性的,本发明的范围由所附权利要求而不是上述说明限定,因此旨在将落在权利要求的等同要件的含义和范围内的所有变化囊括在本发明内。
此外,应当理解,虽然本说明书按照实施方式加以描述,但并非每个实施方式仅包含一个独立的技术方案,说明书的这种叙述方式仅仅是为清楚起见,本领域技术人员应当将说明书作为一个整体,各实施例中的技术方案也可以经适当组合,形成本领域技术人员可以理解的其他实施方式。
Claims (2)
1.含重组人碱性成纤维细胞生长因子无水膏剂制备方法,其特征在于,包括以下步骤:
将甘油添加到冻干粉中,并且混合/搅拌直到所有粉末颗粒都与甘油混合均匀,形成面团状糊剂;然后将丙二醇添加到上述糊剂中,并混合/搅拌,以形成最终的,可流动的膏剂;
所述丙二醇添加到糊剂后还加入羟基磷灰石复合改性蒙脱土,加入量为丙二醇总量5-10%;
所述羟基磷灰石复合改性蒙脱土的制备方法为:
S01:将羟基磷灰石按照重量比1:6加入到十二烷基硫酸钠溶液中,然后加入羟基磷灰石总量5-10%的盐酸,搅拌均匀;
S02:随后加入羟基磷灰石2-5%的壳聚糖、羟基磷灰石1-5%的羟基乙酸,搅拌充分,得到羟基磷灰石复合液;
S03:将蒙脱土送入到350-400℃下热处理10-20min,随后以1-5℃/min的速率降至室温,然后送入到4-6倍的盐酸溶液中,搅拌均匀;
S04:随后加入蒙脱土总量5-10%的羟乙基纤维素、1-5%的氯化镧,搅拌充分,再水洗、干燥;
S05:将S04产物按照重量比1:5送入到S02中,继续反应充分,最后水洗、干燥,得到羟基磷灰石复合改性蒙脱土;
所述冻干粉包括以下重量份原料:
重组人碱性成纤维细胞生长因子 20000-50000IU、蛋白保护剂 5-10mg 和稀释剂50-100mg;
所述蛋白保护剂选自人血白蛋白;
所述稀释剂选自甘露醇、乳糖醇或葡萄糖;
所述冻干粉的制备工艺为:将重组人碱性成纤维细胞生长因子、蛋白保护剂和稀释剂用注射用水溶解后,用 0.22μm 的滤膜无菌过滤,分装于西林瓶中,装盘后送入冻干机中,先将样品在 -20℃--40℃预冻 2-5 小时,然后开启冷凝器,开启真空系统,开始升温升华,完毕后在 15℃-40℃干燥 4-8 小时,即得;
所述甘油、冻干粉、丙二醇的物质质量比为1.2:1:0.5。
2.根据权利要求1所述的含重组人碱性成纤维细胞生长因子无水膏剂制备方法,其特征在于,所述混合/搅拌的转速为550-1000r/min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211625937.9A CN115607506B (zh) | 2022-12-17 | 2022-12-17 | 含重组人碱性成纤维细胞生长因子无水膏剂制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211625937.9A CN115607506B (zh) | 2022-12-17 | 2022-12-17 | 含重组人碱性成纤维细胞生长因子无水膏剂制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115607506A CN115607506A (zh) | 2023-01-17 |
CN115607506B true CN115607506B (zh) | 2023-04-28 |
Family
ID=84880282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211625937.9A Active CN115607506B (zh) | 2022-12-17 | 2022-12-17 | 含重组人碱性成纤维细胞生长因子无水膏剂制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115607506B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117486996B (zh) * | 2023-12-21 | 2024-03-19 | 朗肽生物制药股份有限公司 | 一种改构的重组人酸性成纤维细胞生长因子的制备及其在皮肤修复中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053212A (en) * | 1988-04-20 | 1991-10-01 | Norian Corporation | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
CN115177786A (zh) * | 2022-07-14 | 2022-10-14 | 山东大学 | 一种原位负载蒙脱土/纳米羟基磷灰石的壳聚糖复合支架材料及其制备方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04224522A (ja) * | 1990-04-27 | 1992-08-13 | Merck & Co Inc | 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法 |
GR1002610B (el) * | 1991-01-02 | 1997-02-20 | Johnson & Johnson Consumer Products Inc. | Θεραπευτικες συνθεσεις πληγων που περιεχουν παραγοντα αναπτυξης ινοβλαστων και ασκορβικον οξυ. |
CN101172091B (zh) * | 2007-09-25 | 2011-04-27 | 北京美福源生物医药科技有限公司 | 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途 |
CN1548148A (zh) * | 2003-05-16 | 2004-11-24 | 珠海亿胜生物制药有限公司 | 一种重组人碱性成纤维细胞生长因子胶囊剂及其制备方法 |
CN1733294A (zh) * | 2005-08-10 | 2006-02-15 | 南海朗肽制药有限公司 | 一种重组人碱性成纤维细胞生长因子凝胶剂及其制备方法 |
US20100329995A1 (en) * | 2006-02-21 | 2010-12-30 | Ventria Bioscience | Compositions containing lactoferrin, and methods of using same to promote growth of skin cells |
CN101947309B (zh) * | 2010-04-12 | 2012-09-19 | 南海朗肽制药有限公司 | 人碱性成纤维细胞生长因子滴眼液及其制备方法 |
CN102389402B (zh) * | 2011-11-02 | 2012-12-19 | 珠海亿胜生物制药有限公司 | 外用重组牛碱性成纤维细胞生长因子冻干制剂 |
CN102357242B (zh) * | 2011-11-02 | 2012-12-19 | 珠海亿胜生物制药有限公司 | 重组牛碱性成纤维细胞生长因子凝胶 |
CN102389392B (zh) * | 2011-11-02 | 2012-10-24 | 珠海亿胜生物制药有限公司 | 重组牛碱性成纤维细胞生长因子眼用凝胶 |
CN104667262B (zh) * | 2015-02-12 | 2016-03-23 | 珠海亿胜生物制药有限公司 | 重组牛碱性成纤维细胞生长因子外用溶液 |
CN104586778B (zh) * | 2015-02-12 | 2016-03-23 | 珠海亿胜生物制药有限公司 | 一种外用重组牛碱性成纤维细胞生长因子冻干制剂 |
US10927055B2 (en) * | 2016-02-17 | 2021-02-23 | The Chancellor, Masters And Scholars Of The University Of Oxford | Method of preparing a modified zeolite catalyst and preparing ethylbenzene using one cycle process |
CN106732755B (zh) * | 2016-12-23 | 2019-03-05 | 中节能万润股份有限公司 | 一种分子筛-多元氧化物复合整体挤出式脱硝催化剂的制备方法 |
CN109350735A (zh) * | 2018-07-18 | 2019-02-19 | 吕向阳 | 一种用于疤痕修复的皮肤外用制剂及制备方法和应用 |
CN114805535A (zh) * | 2022-04-21 | 2022-07-29 | 佛山市南海朗肽生物制药工程研究院有限公司 | 一种rh-bFGF冻干方法 |
CN115120784A (zh) * | 2022-06-17 | 2022-09-30 | 朗肽生物制药股份有限公司 | 壳聚糖-氧化海藻酸钠水凝胶材料及其制备方法和应用 |
-
2022
- 2022-12-17 CN CN202211625937.9A patent/CN115607506B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053212A (en) * | 1988-04-20 | 1991-10-01 | Norian Corporation | Intimate mixture of calcium and phosphate sources as precursor to hydroxyapatite |
CN115177786A (zh) * | 2022-07-14 | 2022-10-14 | 山东大学 | 一种原位负载蒙脱土/纳米羟基磷灰石的壳聚糖复合支架材料及其制备方法 |
Non-Patent Citations (5)
Title |
---|
南开辉 ; 王迎军 ; .复合纳米生物医用材料的研究.材料科学与工程学报.2006,(01),第156-159页. * |
杨洪存 ; 曲悦 ; 冯秀萍 ; .重组碱性成纤维细胞生长因子凝胶剂的制备.中国生物制品学杂志.2009,(10),第64-66页. * |
王世岭,周亮,马建丽,杨,潘强,高振梅,高远征,郭华.重组人表皮细胞生长因子凝胶对家兔烫伤创面修复作用的研究.解放军药学学报.2005,(05),第32-35页. * |
石晶,李锐,马玉杰,李世君,连桂凤.冻干重组碱性成纤维细胞生长因子无人血清白蛋白保护剂的研究.中国生化药物杂志.2003,(05),第244-245页. * |
陈钟,吴振宇.纳米材料在组织工程中的应用研究.国外医学.生物医学工程分册.2004,(05),第26-28页. * |
Also Published As
Publication number | Publication date |
---|---|
CN115607506A (zh) | 2023-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9198856B2 (en) | Formulation for stabilizing proteins, which is free of mammalian excipient | |
AU655935B2 (en) | Pharmaceutical composition of florfenicol | |
DE69734653T2 (de) | Pharmazeutische formulierung, bestehend aus menschlichem wachstumshormon, histidine und einem nichtionischen detergenz | |
EP1845787B1 (en) | Formulations for injection of catecholic butanes, including ndga compounds, into animals | |
EP0661989B1 (en) | Sustained-release protein formulations | |
AU2011316111B2 (en) | Formulation suitable for stabilizing proteins, which is free of mammalian excipients | |
BRPI0710315A2 (pt) | dextrano e/ou derivado de dextrano, composição farmacêutica, métodos de tratamento ou formulação de medicamentos, e, utilização de destranos e/ou derivados de dextranos e/ou de composições | |
US20080226724A1 (en) | Prevention of hydrogel viscosity loss | |
CN115607506B (zh) | 含重组人碱性成纤维细胞生长因子无水膏剂制备方法 | |
CN109627463B (zh) | 水凝胶与蛋白质药物 | |
CN104721155B (zh) | 一种替莫唑胺冻干粉制剂及其制备方法 | |
CN102342931A (zh) | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 | |
EP2717885A1 (de) | Antiinfektives mittel | |
JPS58189118A (ja) | 経鼻投与製剤 | |
CN104800172A (zh) | 注射用卡络磺钠粉针剂和制法 | |
EP1156831B1 (de) | Hydroxyethylstärke zur schmerzfreien und gewebeschonenden injektion von arzneimitteln | |
CN112451475B (zh) | 一种用于治疗空洞型肺结核的长效缓释凝胶 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN114601800B (zh) | 一种甲磷丙泊酚钠无菌粉针剂及其制备方法 | |
CN111012734A (zh) | 一种载药网状原位相变凝胶缓释系统及其制备方法 | |
CN113855626B (zh) | 一种用于骨关节炎治疗的辣椒碱注射剂及其制备方法 | |
CN116617155A (zh) | 一种载小球藻提取物的透明质酸水凝胶、其制备方法及应用 | |
CN116350572A (zh) | 可注射原位凝胶缓释递药系统、载药制剂及其制备方法 | |
CN112043818A (zh) | 一种用于皮肤创伤的药物及其制备方法和应用 | |
CN101366701A (zh) | N,n-二甲基甘氨酸-2,6-二异丙基苯酯盐类注射剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Preparation method of anhydrous ointment containing recombinant human alkaline fibroblast growth factor Granted publication date: 20230428 Pledgee: Agricultural Bank of China Limited Foshan Zumiao Sub-branch Pledgor: Long peptide biopharmaceutical Co.,Ltd. Registration number: Y2024980000968 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |